Hidehito HORINOUCHI· @HHorinouchi · X·· 4 小时前评分70
正文 · 原文
🔥Phase 3: Dalmelitinib + aumolertinib vs chemo in EGFR-mutated, MET-amplified NSCLC post-EGFR-TKI
🆙 @JCO_ASCO #ESMO26
🎯Met Primary Endpoint
🎯IRC-PFS 6.2 vs 4.4mo (HR 0.601, p<0.001; n=314)
🎯ORR 59.6% vs 38.6%
🎯OS HR 0.840 (Immature, 46.8% Crossover)
🎯Grade≥3 TEAEs 50.0% vs 51.0%
☑️NCT06110663
🎙Dr. Ziming Li & Dr. Shun Lu
#LCSM @OncoAlert @Larvol @EGFRResisters @metcrusaders
https://ascopubs.org/doi/10.1200/JCO-26-02432
12 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
dalmelitinib + aumolertinib
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org‼️ #ESMO26 simultaneous publication by Lu, et al. Dalmelitinib plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI-Resistance and MET-Amplification: A Randomized Phase 3 Trial Read full publication: https://bit.ly/4z9du0M在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com